ArticleJournal of affective disorders2025
Reliable symptom worsening among veterans receiving cognitive processing therapy or prolonged exposure therapy for posttraumatic stress disorder in routine Veterans Health Administration care.
Article in Journal of affective disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Involvement of Matrix Metalloproteinases (MMP-2 and MMP-9), Inflammasome NLRP3, and Gamma-Aminobutyric Acid (GABA) Pathway in Cellular Mechanisms of Neuroinflammation in PTSD.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Clinical practice guidelines recommend trauma-focused evidence-based psychotherapy (EBP) to treat posttraumatic stress disorder (PTSD). Some veterans and clinicians report concerns that discussion of trauma will make PTSD symptoms worse. We studied the frequency and correlates of reliable symptom worsening during PTSD EBPs in routine clinical practice. Using national electronic health record data from the Veterans Health Administration, we identified veterans (n = 25,768) who initiated PTSD EBP between 1/2018-1/2023 and had PTSD symptom measurements (i.e., PTSD Checklist for DSM-5; PCL-5). We defined reliable symptom worsening as a 10-point PCL-5 increase from baseline. Using hierarchical Bayesian zero inflated binomial logistic regression, we modeled the probability of experiencing reliable symptom worsening across demographic, military, clinical and service delivery characteristics. In our sample, 22.9 % of veterans experienced reliable symptom worsening. However, most demographic, military, clinical, and service delivery characteristics were poorly associated with reliable symptom worsening. One exception was receipt of a first PTSD EBP session in an inpatient setting, which was associated with a lower likelihood of experiencing reliable symptom worsening (MPOR = 0.73, 90 % CI = 0.66, 0.81; 2 % in ROPE). Reliable symptom worsening was an uncommon (but not rare) occurrence during PTSD EBPs and assessed correlates were poorly related to likelihood of experiencing reliable worsening. Further research is needed to understand the drivers of reliable symptom worsening and to compare rates observed in the current study to reliable symptom worsening that occurs naturally over time and that occurs during any PTSD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.